![Franklin P. Bymaster](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Franklin P. Bymaster
Geen lopende functies
Profiel
Mr. Franklin P.
Bymaster is Chief Scientific Officer at Neurovance, Inc. and Chief Scientific Officer at Euthymics Bioscience, Inc.
Mr. Bymaster was previously employed as Vice President-Neuroscience Division by Orexigen Therapeutics, Inc., a Member by Collegium Internationale Neuro-Psychopharmacologicum, a Member by Society For Neuroscience, and Senior Research Scientist by Eli Lilly & Co.
He received his undergraduate degree from Butler University and a graduate degree from Indiana University Bloomington.
Eerdere bekende functies van Franklin P. Bymaster
Bedrijven | Functie | Einde |
---|---|---|
OREXIGEN THERAPEUTICS, INC. | Corporate Officer/Principal | 06-12-2008 |
ELI LILLY AND COMPANY | Hoofd Techniek/Wetenschap/O&O | 01-01-2003 |
Neurovance, Inc.
![]() Neurovance, Inc. Miscellaneous Commercial ServicesCommercial Services Neurovance, Inc. operates as a a biopharmaceutical company. It develops treatments for central nervous system disorders. The company was founded by Anthony McKinney and Franklin P. Bymaster in 2011 and is headquartered in Cambridge, MA. | Oprichter | - |
Euthymics Bioscience, Inc.
![]() Euthymics Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Euthymics Bioscience, Inc. develops a novel medicine for alcohol use disorder (AUD) and smoking cessation. It engages in developing a medicine for central nervous system disorders of significant unmet medical need, including major depressive disorder (MDD) and alcohol use disorder (AUD). The firm provides Amitifadine, an antidepressant for major depressive disorder. The firm focuses on the modulation of neurotransmitters, including serotonin (5-HT), norepinephrine (NE), and dopamine (DA). The company was founded by Anthony A. McKinney and Franklin P. Bymaster in 2009 and is headquartered in Cambridge, MA. | Oprichter | - |
Collegium Internationale Neuro-Psychopharmacologicum | Corporate Officer/Principal | - |
Opleiding van Franklin P. Bymaster
Butler University | Undergraduate Degree |
Indiana University | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
ELI LILLY AND COMPANY | Health Technology |
Bedrijven in privébezit | 5 |
---|---|
Orexigen Therapeutics, Inc.
![]() Orexigen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Orexigen Therapeutics, Inc. is a biopharmaceutical company, which focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its primary activities include recruiting personnel, conducting research and development, including clinical trials, raising capital, and preparing for the marketing and commercialization of its product, contrave. The company was founded by Eckard Weber in September 2002 and is headquartered in La Jolla, CA. | Health Technology |
Society For Neuroscience
![]() Society For Neuroscience Miscellaneous Commercial ServicesCommercial Services The Society for Neuroscience is an organization with over 36,000 members in more than 95 countries. The non-profit company is based in Washington. The organization also engages in science advocacy and public policy, including an annual Capitol Hill Day, and has various public outreach efforts, such as the interactive collection of public-facing resources on BrainFacts.org. It was founded in 1969 and offers year-round programming, including the publication of two scientific journals, professional development resources, and career training through Neuronline. | Commercial Services |
Collegium Internationale Neuro-Psychopharmacologicum | |
Euthymics Bioscience, Inc.
![]() Euthymics Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Euthymics Bioscience, Inc. develops a novel medicine for alcohol use disorder (AUD) and smoking cessation. It engages in developing a medicine for central nervous system disorders of significant unmet medical need, including major depressive disorder (MDD) and alcohol use disorder (AUD). The firm provides Amitifadine, an antidepressant for major depressive disorder. The firm focuses on the modulation of neurotransmitters, including serotonin (5-HT), norepinephrine (NE), and dopamine (DA). The company was founded by Anthony A. McKinney and Franklin P. Bymaster in 2009 and is headquartered in Cambridge, MA. | Commercial Services |
Neurovance, Inc.
![]() Neurovance, Inc. Miscellaneous Commercial ServicesCommercial Services Neurovance, Inc. operates as a a biopharmaceutical company. It develops treatments for central nervous system disorders. The company was founded by Anthony McKinney and Franklin P. Bymaster in 2011 and is headquartered in Cambridge, MA. | Commercial Services |